TNFAIP8 promotes cell growth by regulating the Hippo pathway in epithelial ovarian cancer

Xie,Yao; Zhou,Fei; Zhao,Xia

doi:10.3892/etm.2018.6819

TNFAIP8 promotes cell growth by regulating the Hippo pathway in epithelial ovarian cancer

Authors:
- Yao Xie
- Fei Zhou
- Xia Zhao
View Affiliations

Affiliations: Department of Gynecology and Obstetrics, Key Laboratory of Obstetrics and Gynecologic and Pediatric Diseases and Birth Defects of Ministry of Education, West China Second Hospital, Sichuan University, Chengdu, Sichuan 610041, P.R. China, Department of Gynecology and Obstetrics, Sichuan Academy of Medical Sciences and Sichuan Provincial People's Hospital, Chengdu, Sichuan 610072, P.R. China
Published online on: October 2, 2018 https://doi.org/10.3892/etm.2018.6819
Pages: 4975-4982
Copyright: © Xie et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Tumor necrosis factor‑α‑induced protein 8 (TNFAIP8) is an independent prognostic factor for cancer‑specific and disease‑free survival in patients with epithelial ovarian cancer (EOC). However, the exact mechanism of the biological role of TNFAIP8 in EOC remains unclear. In the present study, a siRNA specifically targeting TNFAIP8 was prepared to knock down TNFAIP8 in EOC cells. Cell growth, colony formation, apoptosis, and cell cycle distribution in TNFAIP8‑deficient EOC cells were determined. In addition, the underlying molecular mechanisms were investigated by western blot analysis and reverse transcription quantitative polymerase chain reaction assays. It was demonstrated that the knockdown of TNFAIP8 inhibited EOC cell growth and colony formation, along with increased levels of apoptosis and cell cycle arrest. The results of the western blot analysis suggested that TNFAIP8 inhibited the expression of phosphorylated yes‑associated protein 1 (YAP) while promoting total and nuclear YAP expression, followed by the regulation of apoptosis and cell cycle checkpoint protein expression in EOC. Overexpression of YAP in EOC cells efficiently attenuated cell growth inhibition in TNFAIP8‑deficient EOC cells. In addition, knockdown of TNFAIP8 significantly impaired EOC tumor growth in vivo. Collectively, the data from the present study suggested that TNFAIP8 is an oncogene and a novel therapeutic target for EOC.

View Figures

View References

1	Siegel RL, Miller KD and Jemal A: Cancer statistics, 2017. CA Cancer J Clin. 67:7–30. 2017. View Article : Google Scholar : PubMed/NCBI
2	Razi S, Ghoncheh M, Mohammadian-Hafshejani A, Aziznejhad H, Mohammadian M and Salehiniya H: The incidence and mortality of ovarian cancer and their relationship with the Human Development Index in Asia. Ecancermedicalscience. 10:6282016. View Article : Google Scholar : PubMed/NCBI
3	Karnezis AN, Cho KR, Gilks CB, Pearce CL and Huntsman DG: The disparate origins of ovarian cancers: Pathogenesis and prevention strategies. Nat Rev Cancer. 17:65–74. 2017. View Article : Google Scholar : PubMed/NCBI
4	Voutsadakis IA: On adjuvant hormone therapy in epithelial ovarian cancer. J Clin Oncol. 34:2070–2071. 2016. View Article : Google Scholar : PubMed/NCBI
5	Chung C and Lee R: An update on current and emerging therapies for epithelial ovarian cancer: Focus on poly (adenosine diphosphate-ribose) polymerase inhibition and antiangiogenesis. J Oncol Pharm Pract. 23:454–469. 2017. View Article : Google Scholar : PubMed/NCBI
6	Rojas V, Hirshfield KM, Ganesan S and Rodriguez-Rodriguez L: Molecular characterization of epithelial ovarian cancer: Implications for diagnosis and treatment. Int J Mol Sci. 17(pii): E21132016. View Article : Google Scholar : PubMed/NCBI
7	Harvey KF, Zhang X and Thomas DM: The Hippo pathway and human cancer. Nat Rev Cancer. 13:246–257. 2013. View Article : Google Scholar : PubMed/NCBI
8	Wierzbicki PM and Rybarczyk A: The Hippo pathway in colorectal cancer. Folia Histochem Cytobiol. 53:105–119. 2015. View Article : Google Scholar : PubMed/NCBI
9	Ma Y, Yang Y, Wang F, Wei Q and Qin H: Hippo-YAP signaling pathway: A new paradigm for cancer therapy. Int J Cancer. 137:2275–2286. 2015. View Article : Google Scholar : PubMed/NCBI
10	Piccolo S, Dupont S and Cordenonsi M: The biology of YAP/TAZ: Hippo signaling and beyond. Physiol Rev. 94:1287–1312. 2014. View Article : Google Scholar : PubMed/NCBI
11	Xia Y, Chang T, Wang Y, Liu Y, Li W, Li M and Fan HY: YAP promotes ovarian cancer cell tumorigenesis and is indicative of a poor prognosis for ovarian cancer patients. PloS One. 9:e917702014. View Article : Google Scholar : PubMed/NCBI
12	Cho SY, Kim K, Park MS, Jang MY, Choi YH, Han S, Shin HM, Chung C, Han HY, Yang JB, et al: Expression of yes-associated protein 1 and its clinical significance in ovarian serous cystadenocarcinoma. Oncol Rep. 37:2620–2632. 2017. View Article : Google Scholar : PubMed/NCBI
13	Jeong GO, Shin SH, Seo EJ, Kwon YW, Heo SC, Kim KH, Yoon MS, Suh DS and Kim JH: TAZ mediates lysophosphatidic acid-induced migration and proliferation of epithelial ovarian cancer cells. Cell Physiol Biochem. 32:253–263. 2013. View Article : Google Scholar : PubMed/NCBI
14	Xia Y, Zhang YL, Yu C, Chang T and Fan HY: YAP/TEAD co-activator regulated pluripotency and chemoresistance in ovarian cancer initiated cells. PloS One. 9:e1095752014. View Article : Google Scholar : PubMed/NCBI
15	Xu M, Xiao J, Chen M, Yuan L, Li J, Shen H and Yao S: miR1495p promotes chemotherapeutic resistance in ovarian cancer via the inactivation of the Hippo signaling pathway. Int J Oncol. 52:815–827. 2018.PubMed/NCBI
16	Yagi H, Asanoma K, Ohgami T, Ichinoe A, Sonoda K and Kato K: GEP oncogene promotes cell proliferation through YAP activation in ovarian cancer. Oncogene. 35:4471–4480. 2016. View Article : Google Scholar : PubMed/NCBI
17	Zhang X, George J, Deb S, Degoutin JL, Takano EA, Fox SB, Bowtell DD and Harvey KF: The Hippo pathway transcriptional co-activator, YAP, is an ovarian cancer oncogene. Oncogene. 30:2810–2822. 2011. View Article : Google Scholar : PubMed/NCBI
18	Lou Y and Liu S: The TIPE (TNFAIP8) family in inflammation, immunity and cancer. Mol Immunol. 49:4–7. 2011. View Article : Google Scholar : PubMed/NCBI
19	Sun H, Lou Y, Porturas T, Morrissey S, Luo G, Qi J, Ruan Q, Shi S and Chen YH: Exacerbated experimental colitis in TNFAIP8-deficient mice. J Immunol. 194:5736–5742. 2015. View Article : Google Scholar : PubMed/NCBI
20	Gao HY, Huo FC, Wang HY and Pei DS: MicroRNA-9 inhibits the gastric cancer cell proliferation by targeting TNFAIP8. Cell Prolif. 50:2017. View Article : Google Scholar
21	Lowe JM, Nguyen TA, Grimm SA, Gabor KA, Peddada SD, Li L, Anderson CW, Resnick MA, Menendez D and Fessler MB: The novel p53 target TNFAIP8 variant 2 is increased in cancer and offsets p53-dependent tumor suppression. Cell Death Differ. 24:181–191. 2017. View Article : Google Scholar : PubMed/NCBI
22	Xiao M, Xu Q, Lou C, Qin Y, Ning X, Liu T, Zhao X, Jia S and Huang Y: Overexpression of TNFAIP8 is associated with tumor aggressiveness and poor prognosis in patients with invasive ductal breast carcinoma. Hum Pathol. 62:40–49. 2017. View Article : Google Scholar : PubMed/NCBI
23	Liu T, Gao H, Chen X, Lou G, Gu L, Yang M, Xia B and Yin H: TNFAIP8 as a predictor of metastasis and a novel prognostic biomarker in patients with epithelial ovarian cancer. Br J Cancer. 109:1685–1692. 2013. View Article : Google Scholar : PubMed/NCBI
24	Liu T, Xia B, Lu Y, Xu Y and Lou G: TNFAIP8 overexpression is associated with platinum resistance in epithelial ovarian cancers with optimal cytoreduction. Hum Pathol. 45:1251–1257. 2014. View Article : Google Scholar : PubMed/NCBI
25	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
26	Dai L, Cui X, Zhang X, Cheng L, Liu Y, Yang Y, Fan P, Wang Q, Lin Y, Zhang J, et al: SARI inhibits angiogenesis and tumour growth of human colon cancer through directly targeting ceruloplasmin. Nat Commun. 7:119962016. View Article : Google Scholar : PubMed/NCBI
27	Sun Z, Liu X, Song JH, Cheng Y, Liu Y, Jia Y, Meltzer SJ and Wang Z: TNFAIP8 overexpression: a potential predictor of lymphatic metastatic recurrence in pN0 esophageal squamous cell carcinoma after Ivor Lewis esophagectomy. Tumour Biol. 37:10923–10934. 2016. View Article : Google Scholar : PubMed/NCBI
28	Dong Q, Fu L, Zhao Y, Xie C, Li Q and Wang E: TNFAIP8 interacts with LATS1 and promotes aggressiveness through regulation of Hippo pathway in hepatocellular carcinoma. Oncotarget. 28:15689–15703. 2017.
29	Han Y, Tang Z, Zhao Y Li Q and Wang E: TNFAIP8 regulates Hippo pathway through interacting with LATS1 to promote cell proliferation and invasion in lung cancer. Mol Carcinog. 57:159–166. 2018. View Article : Google Scholar : PubMed/NCBI
30	Xing B and Ren C: Tumor-suppressive miR-99a inhibits cell proliferation via targeting of TNFAIP8 in osteosarcoma cells. Am J Transl Res. 8:1082–1090. 2016.PubMed/NCBI
31	Hall CA, Wang R, Miao J, Oliva E, Shen X, Wheeler T, Hilsenbeck SG, Orsulic S and Goode S: Hippo pathway effector Yap is an ovarian cancer oncogene. Cancer Res. 70:8517–8525. 2010. View Article : Google Scholar : PubMed/NCBI
32	Kim M and Jho EH: Cross-talk between Wnt/β-catenin and Hippo signaling pathways: A brief review. BMB reports. 47:540–545. 2014. View Article : Google Scholar : PubMed/NCBI